by Ethan Perlstein | Mar 13, 2018 | Business |
Economies of scale are the efficiencies unlocked by large numbers. I’ve come to realize that the efficiencies of scale can emerge at the opposite extreme of rare – especially ultra-rare – genetic disease communities, which can number as few as dozens to thousands of...
by Sangeetha Iyer | Mar 11, 2016 | Blogposts |
Today’s post will focus on the vision for PLab. Let’s start with a basic statistical concept- long tail distribution. While this form of frequency distribution has been around since the 1940’s, it gained prominence in fields outside of insurance and...
by Kiran Singh | Jun 10, 2015 | Science |
In our last post we talked specifically about orphan drugs that are small molecules. In this post I’ll address the orphan drugs that are biologics. They behave differently: There’s a possible increase in cost/year around 2006 but it doesn’t seem to remain...
![Orphan drug prices and approvals]()
by Kiran Singh | Jun 2, 2015 | Science |
This post kicks off a series about drug prices in the orphan drug space. We initially wanted to get a sense of orphan drug price trends over the last 30 years — since the passage of the Orphan Drug Act of 1983. There were a few published industry reports...
